Clinical Trials Browser

Phase 2 × Has results × pazopanib × Clear all

NCT01841736 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors

Phase 2 Active not recruiting

171 enrolled 15 charts

Neuroendocrine Tumors

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01147822 2025-03-28

Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma

Phase 2 Completed

367 enrolled 14 charts

Carcinoma, Renal Cell

NCT01767636 2025-03-03

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer

Phase 2 Completed

38 enrolled 12 charts

Oncocytoma, renal, Carcinoma, Renal Cell

NCT02207309 2024-08-09

Pazopanib Maintenance Phase II

Phase 2 Terminated

1 enrolled 4 charts

Sarcoma

NCT00827372 2023-10-16

A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer

Phase 2 Completed

10 enrolled 10 charts

Lymphedema

NCT03200717 2023-08-21

IO-PAZ

Phase 2 Completed

62 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01330966 2023-03-10

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

Phase 2 Completed

47 enrolled 10 charts

Chondrosarcoma

NCT01462630 2022-08-19

Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma

Phase 2 Completed

29 enrolled 10 charts

Hemangiosarcoma, Sarcoma

NCT01157091 2022-06-08

Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer

Phase 2 Completed

28 enrolled 10 charts

Carcinoma, Renal Cell

NCT01664182 2022-06-07

Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer

Phase 2 Completed

41 enrolled 13 charts

Carcinoma, Renal Cell

NCT02357810 2022-06-07

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

Phase 2 Completed

178 enrolled 16 charts

Liposarcoma, Sarcoma, Osteosarcoma

NCT03334409 2022-03-31

Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 2 Terminated

5 enrolled 16 charts

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT02212015 2022-03-22

EVA

Phase 2 Terminated

26 enrolled 16 charts

Hemangiosarcoma

NCT01532687 2021-09-27

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

Phase 2 Completed

54 enrolled 12 charts

Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

Phase 2 Completed

69 enrolled 15 charts

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT01610206 2021-02-25

A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer

Phase 2 Completed

148 enrolled 11 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT01956669 2020-08-12

Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors

Phase 2 Completed

57 enrolled 22 charts

Sarcoma

NCT02300545 2020-08-05

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

Phase 2 Completed

56 enrolled 11 charts

Sarcoma

NCT02193152 2020-07-14

Pazopanib in Molecularly Selected Patients With Advanced NSCLC

Phase 2 Terminated

16 enrolled 9 charts

Carcinoma, Non-Small-Cell Lung

NCT01466972 2020-07-08

Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib

Phase 2 Completed

30 enrolled 11 charts

Breast Neoplasms, Neoplasms

NCT01593748 2020-04-06

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

Phase 2 Completed

90 enrolled 12 charts

Sarcoma

NCT00454363 2020-04-03

Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer

Phase 2 Completed

52 enrolled 11 charts

Glucagonoma, Insulinoma, Somatostatinoma, Zollinger-Ellison Syndrome, Multiple Endocrine Neoplasia Type 1

NCT00625846 2020-02-26

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Phase 2 Completed

152 enrolled 16 charts

EndocrineHead & Neck

Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT01247571 2019-08-08

Pazopanib Hydrochloride in Treating Patients With Recurrent or Persistent Uterine Cancer

Phase 2 Completed

22 enrolled 8 charts

GynecologicSarcoma

Recurrent Uterine Corpus Sarcoma

NCT01107665 2019-08-07

Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma

Phase 2 Completed

60 enrolled 16 charts

Melanoma

NCT01280201 2019-05-29

Pazopanib as Single Agent in Advanced NETs

Phase 2 Completed

44 enrolled 17 charts

Neuroendocrine Tumors

NCT01253369 2019-04-23

Pazopanib in Patients With Relapsed or Refractory Small Cell Lung Cancer

Phase 2 Completed

33 enrolled 8 charts

Lung Neoplasms, Small Cell Lung Carcinoma

NCT01832259 2018-12-12

A Study of VEGF Tyrosine Kinase Inhibitor (Pazopanib) in Men With High-Risk Prostate Cancer Followed by Radical Prostatectomy and Pelvic Lymph Node Dissection

Phase 2 Completed

30 enrolled 10 charts

Adenocarcinoma of the Prostate

NCT00861913 2018-10-16

Pazopanib Hydrochloride in Treating Patients With Metastatic Melanoma That Cannot be Removed by Surgery

Phase 2 Completed

13 enrolled 8 charts

Melanoma

NCT02560012 2018-10-12

Personalized Targeted Inhibitors Treatment in Renal Cell Cancer

Phase 2 Terminated

4 enrolled 3 charts

Carcinoma, Renal Cell

NCT00281632 2018-09-17

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Phase 2 Completed

35 enrolled 24 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT01158521 2018-09-12

Pazopanib Hydrochloride Before Surgery in Treating Patients With Kidney Cancer

Phase 2 Completed

25 enrolled 8 charts

Carcinoma, Renal Cell

NCT00509587 2018-08-08

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Phase 2 Completed

21 enrolled 10 charts

Breast Neoplasms

NCT01394211 2018-07-26

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Phase 2 Terminated

2 enrolled 3 charts

Breast Neoplasms, Breast Neoplasms, Male

NCT01361113 2018-04-25

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Phase 2 Completed

21 enrolled 10 charts

Carcinoma, Renal Cell

NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Phase 2 Terminated

7 enrolled 8 charts

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

NCT01622660 2017-08-22

Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy

Phase 2 Terminated

2 enrolled 9 charts

Urinary Bladder Neoplasms

NCT01108055 2017-06-09

Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer

Phase 2 Completed

43 enrolled 16 charts

Urinary Bladder Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01391611 2017-04-07

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Phase 2 Terminated

25 enrolled 7 charts

GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT00459381 2017-03-15

Pazopanib in Treating Patients With Recurrent Glioblastoma

Phase 2 Completed

35 enrolled 12 charts

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT01262820 2017-03-07

LCCC0921

Phase 2 Completed

15 enrolled 10 charts

Lung Neoplasms

NCT01506596 2017-02-15

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma

Phase 2 Completed

42 enrolled 9 charts

Liposarcoma

NCT00347919 2016-02-25

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Phase 2 Completed

189 enrolled 15 charts

Breast Neoplasms, Neoplasm Metastasis

NCT00454571 2016-02-10

Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prostate Cancer

Phase 2 Completed

37 enrolled 5 charts

Prostatic Neoplasms

NCT00297258 2016-02-03

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Phase 2 Completed

148 enrolled 8 charts

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial

NCT01027598 2016-01-29

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

Phase 2 Completed

202 enrolled 8 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT00454142 2015-12-17

Pazopanib Hydrochloride in Treating Patients With Stage IV or Recurrent Nasopharyngeal Cancer

Phase 2 Completed

33 enrolled 18 charts

Recurrent Lymphoepithelioma of the Nasopharynx

NCT01080248 2015-06-09

Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer

Phase 2 Terminated

2 enrolled 5 charts

Gastrointestinal

Pancreatic Neoplasms

NCT00731211 2015-05-20

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

Phase 2 Completed

57 enrolled 6 charts

Carcinoma, Renal Cell, Neoplasm Metastasis